Showing 6201-6210 of 10817 results for "".
- Lutikizumab Improves Clinical Response Rates in Moderate to Severe HS: Analysishttps://practicaldermatology.com/news/lutikizumab-shows-promise-in-hs-after-anti-tnf-failure-in-phase-2-trial/2486330/In a phase 2, double-blind, placebo-controlled randomized clinical trial, lutikizumab demonstrated efficacy signals in adults with moderate to severe hidradenitis suppurativa (HS) who had previously experienced anti–tumor necrosis factor (TNF) therapy failure.
- FDA Approves Icotrokinra for Moderate-to-Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-icotyde-for-moderate-to-severe-plaque-psoriasis/2486305/Johnson & Johnson announced that the FDA has approved ICOTYDE (icotrokinra) for the treatment of moderate-to-severe plaque psoriasis in adults and in pediatric patients 12 years and older who weigh at least 40 kg and are candidates for systemic therapy or phot
- ADorable-1 Trial Meets Endpoints for EBGLYSS in Children With Atopic Dermatitishttps://practicaldermatology.com/news/adorable-1-trial-meets-endpoints-for-ebglyss-in-children-with-atopic-dermatitis/2486087/Eli Lilly and Company announced positive topline results from the phase 3 ADorable-1 trial of lebrikizumab-lbkz (Ebglyss) in pediatric patients aged 6 months to 18 years with moderate-to-severe atopic dermatitis (AD), showing the therapy meeting its primary and sec
- INTEGUMENT-OLE Data Show Sustained Efficacy of Roflumilast in Early Childhood ADhttps://practicaldermatology.com/news/integument-ole-data-show-sustained-efficacy-of-roflumilast-in-early-childhood-ad/2486045/The 56-week phase 3 open-label extension for the INTEGUMENT trial (INTEGUMETN-OLE) indicated once-daily roflumilast cream 0.05% maintained efficacy and demonstrated favorable long-term safety in children aged 2 to 5 years with mild-to-moderate atopic dermatitis (AD
- BE BOLD: Bimekizumab Shows Superiority Over IL-23 Inhibitor in Psoriatic Arthritishttps://practicaldermatology.com/news/be-bold-trial-bimekizumab-shows-superiority-over-il-23-inhibitor-in-psoriatic-arthritis/2486038/Bimekizumab achieved statistically significant superiority over risankizumab in reducing disease activity at Week 16 in adults with active psoriatic arthritis (PsA), according to topline results from the phase 3 BE BOLD head-to-head trial announced by UCB.
- Baricitinib, Ritlecitinib, and Deuruxolitinib Demonstrate Efficacy in Severe AAhttps://practicaldermatology.com/news/baricitinib-ritlecitinib-and-deuruxolitinib-demonstrate-efficacy-in-severe-aa/2485957/An analysis of clinical trials reports that Janus kinase (JAK) inhibitors shows significant efficacy and manageable safety profiles in treating severe alopecia areata (AA). Alopecia areata (AA) is an autoimmune disorder charac
- Diclofenac, Silymarin Show Promise for Preventing Chemotherapy-Induced Hand-Foot Syndrome: Meta-analysishttps://practicaldermatology.com/news/diclofenac-silymarin-show-promise-for-preventing-chemotherapy-induced-hand-foot-syndrome-meta-analysis/2485939/Diclofenac and topical silymarin reduced the risk of grade 2 or higher chemotherapy-induced hand-foot syndrome (HFS), according to a new meta-analysis of randomized clinical trials evaluating pharmacologic preventive strategies.
- Arcutis Launches First-in-Human Trial of CD200R Agonist ARQ-234 in Atopic Dermatitishttps://practicaldermatology.com/news/arcutis-launches-first-in-human-trial-of-cd200r-agonist-arq-234-in-atopic-dermatitis/2485894/Arcutis Biotherapeutics announced today that it has enrolled the first participant in a phase 1a/1b clinical trial evaluating ARQ-234, an investigational CD200 receptor (CD200R) agonist, in healthy volunteers and adults with moderate to severe atopic dermatitis (AD
- Phase 3: QTORIN™ Rapamycin Meets All Primary, Secondary Endpoints in Microcystic Lymphatic Malformationshttps://practicaldermatology.com/news/phase-3-qtorin-rapamycin-meets-all-primary-secondary-endpoints-in-microcystic-lymphatic-malformations/2485806/Palvella Therapeutics, Inc. announced positive topline results from the Phase 3 SELVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel for microcystic lymphatic malformations (microcystic LMs), a rare, congenital vascular anomaly with no US Food and Drug Admin
- Remibrutinib Data at AAAAI Suggests Potential Expansion Beyond CSUhttps://practicaldermatology.com/news/remibrutinib-data-at-aaaai-highlight-expanded-potential-beyond-csu/2485784/New data on the selective Bruton’s tyrosine kinase inhibitor remibrutinib (Rhapsido) is slated for presentation at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, to be held February 27 to March 2 in Philadelphia.